Lv1
100 积分 2021-06-24 加入
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
4天前
求助中
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: combination of HX008 and niraparib in GErm-line-mutAted metastatic breast cancer
26天前
已完结
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck: A Multicenter, Phase IIa Trial
1个月前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
1个月前
已完结
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
2个月前
已完结
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
2个月前
已完结
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
2个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
2个月前
已完结
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164
2个月前
已完结
Pucotenlimab: First Approval
3个月前
已完结
皖公网安备34019202002308